Preventive Screening & Blood Biomarkers • ICD-10-CM Z22.322
Methicillin-resistant Staph aureus (MRSA) colonization
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM Z22.322 • 3 Linked .gov / PubMed Citations
•
Governance: Dr. Devon Caldwell, DO, MPH (NPI #1568063758)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Methicillin-resistant Staph aureus (MRSA) colonization Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Methicillin-resistant Staph aureus (MRSA) colonization (ICD-10-CM Z22.322), Preventive Screening & Blood Biomarkers protocols prioritize evidence-based risk stratification in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: pairing lifestyle nutrition/exercise) paired with baseline and interval ApoB, HbA1c & in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: hs-CRP Triad) assessment.
- 2 Real-world patient consensus: Mapped to Preventive Screening & Blood Biomarkers under ICD-10-CM Z22.322 for Methicillin-resistant Staph aureus (MRSA) colonization clinical workups.
- 3 Typical cash cost range: Workup highlights for Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322): evidence-based risk stratification in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: pairing lifestyle nutrition/exercise).
- 4 Top reported side effects / signs: Longitudinal Methicillin-resistant Staph aureus (MRSA) colonization monitoring tracks ApoB, HbA1c & in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: hs-CRP Triad) toward ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (Z22.322).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Methicillin-resistant Staph aureus (MRSA) colonization
What Is Methicillin-resistant Staph aureus (MRSA) colonization?
For patients presenting with Methicillin-resistant Staph aureus (MRSA) colonization (ICD-10-CM Z22.322), Preventive Screening & Blood Biomarkers protocols prioritize evidence-based risk stratification in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: pairing lifestyle nutrition/exercise) paired with baseline and interval ApoB, HbA1c & in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: hs-CRP Triad) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322) center on or micronutrient cofactor in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: reserves years prior). targeted preventive & labs interventions aim to normalize ApoB, HbA1c & in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: hs-CRP Triad).
Common Symptoms & Clinical Signs
- • Presentation of Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322): subtle fatigue, recovery in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: lag, or micronutrient)
- • Secondary Methicillin-resistant Staph aureus (MRSA) colonization clinical sign: age- or family-history-guided in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: cancer, vascular, bone,)
- • Symptom flares in Methicillin-resistant Staph aureus (MRSA) colonization correlating with ApoB, HbA1c & in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: hs-CRP Triad) deviation outside ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (Z22.322)
- • Functional preventive & labs impact requiring evidence-based risk stratification in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: pairing lifestyle nutrition/exercise) evaluation (Z22.322)
Methicillin-resistant Staph aureus (MRSA) colonization Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Z22.322 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Preventive Screening & Blood Biomarkers | NLM Clinical Tables |
| Diagnostic / Lab Marker: ApoB, HbA1c & in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: hs-CRP Triad) | ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (Z22.322) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC, CMP & in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: eGFR Baseline) | Within optimal preventive reference intervals (Z22.322) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D, in Methicillin-resistant Staph aureus (MRSA) colonization (Z22.322: Ferritin & B12) | 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (Z22.322) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Methicillin-resistant Staph aureus (MRSA) colonization
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Gentamicin Garamycin • RxCUI 1870676 | Aminoglycoside Antibacterial | 87% | $1.2576 | $ 8.74 /mo |
| Cefdinir Omnicef • RxCUI 200346 | Cephalosporin Antibacterial | 87% | $0.4454 | $ 12.19 /mo |
| Aztreonam Azactam, Cayston • RxCUI 1664981 | Monobactam Antibacterial | 82% | $2.1600 | $ 95.98 /mo |
| Cabazitaxel Jevtana • RxCUI 1001433 | FDA Prescription Therapeutic Agent | 74% | $2.4100 | $ 106.11 /mo |
| Erythromycin Ery-Tab, A/T/S • RxCUI 197650 | Macrolide | 75% | $1.6915 | $ 13.19 /mo |
| Radium Ra 223 Dichloride Xofigo • RxCUI 1424214 | Radioactive alpha-Particle Emitting Therapeutic Agent | 87% | $2.3400 | $ 103.27 /mo |
| Rifaximin Xifaxan • RxCUI 429662 | Rifamycin Antibacterial | 75% | $2.9700 | $ 128.79 /mo |
| Sulfamethoxazole, Trimethoprim Sulfamethox-Tmp Ds, Bactrim • RxCUI 198335 | Sulfonamide Antimicrobial | 84% | $0.0475 | $ 5.92 /mo |
| Amoxicillin Amoxil • RxCUI 308189 | Penicillin-class Antibacterial | 83% | $0.0179 | $ 6.38 /mo |
| Trimethoprim Proloprim • RxCUI 198332 | Dihydrofolate Reductase Inhibitor Antibacterial | 92% | $1.1409 | $ 52.01 /mo |
| Neomycin Sulfate Single Antibiotic with Neomycin, Antibiotic • RxCUI 866042 | Aminoglycoside Antibacterial | 74% | $0.8307 | $ 29.72 /mo |
| Hydroxyurea Droxia, Hydrea • RxCUI 197797 | Antimetabolite | 87% | $0.1836 | $ 8.23 /mo |
| Abiraterone Zytiga • RxCUI 1100075 | Cytochrome P450 17A1 Inhibitor | 80% | $0.7741 | $ 19.23 /mo |
| Penicillin G Benzathine Bicillin L-A • RxCUI 731564 | Penicillin-class Antibacterial | 92% | $0.0442 | $ 10.29 /mo |
| Doxycycline Doxy 100, Oracea • RxCUI 1649990 | Tetracycline-class Drug | 90% | $0.2285 | $ 137.25 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Methicillin-resistant Staph aureus (MRSA) colonization)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Disease and Treatment-Related Burden in Patients With Acromegaly Who Are GI side effects and ISRs were also common. Frontiers in endocrinology • 2021-01-15 • Phase III Randomized Trial | N = 91 | 82/100 | PMID 33790860 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Methicillin-resistant Staph aureus (MRSA) colonization Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Methicillin-resistant Staph aureus (MRSA) colonization community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Methicillin-resistant Staph aureus (MRSA) colonization.